ROWLAND LLOYD A 4
4 · CytomX Therapeutics, Inc. · Filed Dec 19, 2023
Insider Transaction Report
Form 4
ROWLAND LLOYD A
General Counsel
Transactions
- Exercise/Conversion
Common Stock
2023-12-17+11,250→ 102,073 total - Exercise/Conversion
Performance Stock Units (PSUs)
2023-12-17−11,250→ 11,250 total→ Common Stock (11,250 underlying)
Footnotes (4)
- [F1]Represents partial vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.
- [F2]Includes 41,875 restricted stock units.
- [F3]Includes 4,560 shares and 5,654 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2023 and November 30, 2023, respectively.
- [F4]Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024.